- Advertise
- Contact Us
- Editorial Info
- Terms and Conditions
- Privacy Policy
- Do Not Sell My Personal Information
© 2023 MJH Life Sciences™ and Practical Cardiology. All rights reserved.
Heart Disease and Diabetes
The Practical Cardiology™ Heart Disease and Diabetes clinical resource center offers readers the latest in the field of diabetes and cardiovascular disease. With the field of cardiometabolic health becoming a focal point in the fight against cardiovascular disease, this page will host content related to the latest FDA approvals, studies, guideline update, and clinical perspectives from advisory board members.
Exploring Racial/Ethnic Disparities in Arterial Stiffness in Youth with Type 1 Diabetes
June 07, 2022
Katherine Sauder, PhD, provides perspective on an ADA 2022 study she led examining racial/ethnic disparities in arterial stiffness among youths with type 1 diabetes in the US.
Empagliflozin Provides Greater HF Risk Reduction than Other Glucose-Lowering Agents
June 06, 2022
A 5-year monitoring program, data from the EMPRISE study detail the comparative risk reductions provided by empagliflozin against GLP-1 RAs or DPP-4 inhibitors for heart failure hospitalizations.
No Red Flags for Fracture Risk with SGLT2 Inhibitors in Diabetic Kidney Disease
May 31, 2022
An analysis of data from more than 75,000 patients with diabetic kidney disease details the risk of fracture among new users of SGLT2 inhibitors compared to new users of DPP-4 inhibitors.
Metformin, Lifestyle Changes Not Enough to Stave off CVD Risk in T2D
May 27, 2022
Data from an analysis of follow-up data from the landmark DPPOS study provide insight into the apparent lack of cardiovascular risk reduction provided to patients with prediabetes from metformin and lifestyle interventions.
Arterial Stiffness a Better Predictor of T2D Risk than Blood Pressure in Chinese Patients
May 16, 2022
An analysis of data from more than 11,000 patients in China suggests arterial stiffness could be a better predictor of type 2 diabetes risk than other traditional risk factors, such as hypertension.
Early Glycemic Control Can Help Stave Off Cardiovascular Risk in Type 2 Diabetes
May 12, 2022
A retrospective analysis of more than 25k patients with type 2 diabetes details the impact achieving early glycemic control can have on the risk of cardiovascular disease events among these patients.
Uncontrolled Blood Pressure, HbA1c Common Among Hospitalized Heart Failure Patients
May 09, 2022
An analysis of NHANES surveys from 2001-2018 describes the overall prevalence of uncontrolled hypertension and HbA1c in adults with heart failure and provides insight into racial/ethnic disparities in prevalence.
SGLT2 Inhibitor Prescriptions Increasing Among Cardiologists, Still Room for Improvement
April 28, 2022
An analysis of national prescription data suggests the number of prescriptions for SGLT2 inhibitors from cardiologists increased 12-fold from 2015 to 2020 while prescriptions for GLP-1 RAs increased 4-fold during the same period.
Cognitive Impairment in Diabetes Could Increase Risk of Cardiovascular Disease
April 25, 2022
An analysis of the REWIND trial suggests baseline cognitive impairment was associated with a 1.6 times greater risk of major adverse cardiovascular events among patients with type 2 diabetes.
Plant-Based Diets Can Reduce Risk of Type 2 Diabetes
April 15, 2022
A diet composed of healthy, plant-based foods is associated with a lower risk of developing type 2 diabetes, according to a recent study from the Harvard T.H. Chan School of Public Health.